141735-24-2

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 314728-04-6 (S)-2-benzyloxycarbonylamino-4-hydroxybutyric acid methyl ester 
• 35677-88-4 N-benzyloxycarbonyl-(L)-homoserine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 141735-25-3 {(3E,5E)-(1S,2S)-6-(4-Bromo-phenyl)-1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-hydroxy-4-methyl-hexa-3,5-dienyl}-carbamic acid benzyl ester 
• 141735-26-4 {(3Z,5E)-(1S,2S)-6-(4-Bromo-phenyl)-1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-hydroxy-4-methyl-hexa-3,5-dienyl}-carbamic acid benzyl ester 
• 634587-10-3 [(S)-1-((4S,5R)-2,2-Dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-3-hydroxy-propyl]-carbamic acid benzyl ester 
• 634587-14-7 [(S)-1-((4S,5R)-2,2-Dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-3-iodo-propyl]-carbamic acid benzyl ester 
• 634586-98-4 {(Z)-(S)-1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-heptadec-2-enyl}-carbamic acid benzyl ester 
• 634587-01-2 (3S,4S,5R)-1-O-(tert-butyldimethylsilyl)-3-[(benzyloxycarbonyl)amino]-4,5-nonadecanediol 
• 634587-04-5 (3S,4R,5S)-1-O-(tert-butyldimethylsilyl)-3-[(benzyloxycarbonyl)amino]-4,5-nonadecanediol 
• 634587-07-8 [(S)-3-(tert-Butyl-dimethyl-silanyloxy)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-propyl]-carbamic acid benzyl ester 
• 634587-28-3 (4S,5S)-3-Benzyl-4-[2-((2R,3S,4S,5S,6R)-3,4-bis-benzyloxy-5-hydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-ethyl]-5-((R)-1-hydroxy-pentadecyl)-oxazolidin-2-one 
• 634587-19-2 [(S)-3-[(2S,4aR,6S,7R,8R,8aR)-7,8-Dihydroxy-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-ylsulfanyl]-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-propyl]-carbamic acid benzyl ester 
• 634587-17-0 Acetic acid (2R,3S,4S,5R,6S)-3,5-diacetoxy-2-acetoxymethyl-6-[(S)-3-benzyloxycarbonylamino-3-((4S,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-propylsulfanyl]-tetrahydro-pyran-4-yl ester 
• 762262-42-0 Benzyl-[(S)-3-((2S,3R,4S,5S,6R)-3,4-bis-benzyloxy-5-hydroxy-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-2-yl)-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-propyl]-carbamic acid benzyl ester 
• 634587-27-2 Benzoic acid (2R,3S,4S,5S,6R)-6-[(S)-3-(benzyl-benzyloxycarbonyl-amino)-3-((4S,5R)-2-oxo-5-tetradecyl-[1,3]dioxolan-4-yl)-propyl]-4,5-bis-benzyloxy-3-hydroxy-tetrahydro-pyran-2-ylmethyl ester 
• 762262-41-9 Benzyl-[(S)-3-[(2S,4aR,7R,8S,8aS)-7,8-bis-benzyloxy-2-(4-methoxy-phenyl)-tetrahydro-pyrano[3,2-d][1,3]dioxin-(6Z)-ylidene]-1-((4S,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-propyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

The C-glycoside analogue of the immunostimulant α-galactosylceramide (KRN7000): Synthesis and striking enhancement of activity

Which source provides the better drug? The fully synthetic C-glycoside I (Y=CH2) is about 1000 times more potent against malaria in mice than the corresponding O-glycoside (Y=O), which is derived from a natural product and itself known to show remarkable activity against a wide range of diseases. The results of comparative biological assays emphasize the potential of C-glycosides as therapeutic agents.

Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases

The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, a

SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES

The invention is directed to compounds of formula (I) wherein X is O, OR NH; R' is a hydrocarbon chain; R and are hydrogen, OH or a monosaccharide; R is hydrogen or a monosaccharide; Q' is optionally present and may be a C1-10 hydrocarbon; X' i